Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a
regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with
relapsed multiple myeloma.